Cabaletta Bio (CABA) News
NASDAQ: CABAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CABA news summary
We found 6 recent headlines mentioning Cabaletta Bio (CABA): 0 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire. CABA is making an outsized move today, down 7.32% at $0.9361, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cabaletta Bio headlines
- Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026Cabaletta Bio, Inc. announced new Phase 1/2 clinical data for resecabtagene autoleucel, also known as rese-cel, at the American College of Rheumatology Convergence 2026 annual meeting. The clinical…NasdaqCABA, BF.A
- Cabaletta Bio Reports Positive Phase 1/2 Data For Rese-cel In Autoimmune Diseases; Stock Up(RTTNews) - Cabaletta Bio, Inc. (CABA), a late-stage clinical biotechnology company, announced new positive Phase 1/2 clinical data for investigational resecabtagene autoleucel (rese-cel). Rese-cel…NasdaqCABA, ET
- Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroidsGlobeNewswire
- Cabaletta Bio, Inc. Reports Third Quarter 2026 Financial Results and $299.4 million Cash PositionCabaletta Bio, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided a business update. As of September 30, 2026, the company had cash and cash equivalents…Nasdaq
- Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateRESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2…GlobeNewswire
- Cabaletta Bio to Participate in Upcoming Investor ConferencesPHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies…GlobeNewswire